Halofuginone hydrobromide

Key Product Details

Product Description

Halofuginone hydrobromide is a high affinity competitive prolyl-tRNA synthetase inhibitor (K_i = 18.3 nM). Blocks expression of MMP2. Inhibits ECM invasion in vitro and lung metastasis by bladder cancer cells in mice. Inhibits the development of Th17-driven autoimmunity in a mouse model of multiple sclerosis by activating the amino acid response (AAR) pathway. Also antiparasitic.

Product Specifications for Halofuginone hydrobromide

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for Halofuginone hydrobromide

The following data is based on the product molecular weight 495.59.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.02 mL	10.09 mL	20.18 mL
5 mM	0.40 mL	2.02 mL	4.04 mL
10 mM	0.20 mL	1.01 mL	2.02 mL
50 mM	0.04 mL	0.20 mL	0.40 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 130 publications citing the usage of this product.

• Elkin Inhibition of matrix metalloproteinase-2 expression and bladder carcinoma metastasis by halofuginone. Clin.Cancer.Res. 1999 PMID: 10473075
• Keller Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase. Nat Chem Biol. 2012 PMID: 22327401
• Anderson Analysis of the anti-coccidial drug, halofunginone, in chicken feed using gas-liquid chromatography and high-performance liquid chromatography. J.Chromatogr. 1979 PMID: 570196

Product Documents for Halofuginone hydrobromide